Drug Trial Radar · NCT05913947
Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
122
Planned (sponsor's estimate)
Start
Dec 13, 2022
Primary completion
Sep 1, 2028
Study completion Sep 2, 2028
Sponsor
- Lead sponsor
- Aalborg University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Glostrup University Hospital, Copenhagen; Mental Health Department Odense, University Clinic; Psychiatric Center Copenhagen, Rigshospitalet; Psychiatric Hospital, Hillerod
- First posted
- Jun 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal is to study the effect of lithium compared to cariprazine in patients with depression in a bipolar disease. The main question it aims to answer is: Difference in change between the two groups from baseline to after 8 weeks treatment on Hamilton Ratings Scale for Depression, 6-item version (HDS-6) Participants will be randomized to treatment with either lithium or cariprazin. * Will meet for interview and ratings 4 times during study period. * In two meetings, there will be made blood samples and ECG. At one meeting also a Urine sample. * Will be contacted for telephone interviews at 6 occasions.
Conditions
- Depression, Bipolar
Interventions
LithiumDrug
The starting dose (day one) of lithium citrate is 12 mmol (one tablet of lithium citrate contains 6 mmol lithium) given once a day before bedtime. On day three the dose is increased to 18 mmol. Dose adjustments are permitted after 7 days in a flexible manner to result in a 12-hour se-lithium between 0.6 and 0.8 mmol/l, aiming for the upper limit at the treating physician's discretion.
CariprazineDrug
The starting dose for cariprazine is 1.5 mg daily in a single dose, and subsequently, after a minimum of two weeks, the dose can be increased to 3 mg and decreased again to 1.5 mg daily at the treating physician's discretion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Hamilton Depressions scale, version 6 (HDS-6)Time frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aalborg University Hospital
Aalborg, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.